johnson-and-johnson
(2)
Johnson & Johnson
It stopped making the Band-Aid. What is left is a $94-billion bet that the future of Johnson & Johnson is written on a prescription pad and a robotic arm.
Protagonist Therapeutics
Protagonist Therapeutics is a Newark, California clinical-stage biopharmaceutical company that turns peptides - short chains of amino acids long dismissed as too fragile to be drugs - into stable, often orally available medicines. Its proprietary peptide discovery and engineering platform powers a pipeline spanning hematology, inflammation/immunology and metabolic disease, anchored by rusfertide (a hepcidin mimetic for polycythemia vera under FDA Priority Review) and icotrokinra, an oral IL-23 receptor blocker partnered with Johnson & Johnson that reached the U.S. market in 2026. Publicly traded on Nasdaq as PTGX, the company pairs internal discovery with high-value pharma partnerships.